Scorpius Holdings, Inc. (SCPX)
| Market Cap | 5.66M |
| Revenue (ttm) | 2.23M |
| Net Income (ttm) | -51.96M |
| Shares Out | 36.03M |
| EPS (ttm) | -2.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 142,776 |
| Open | 0.159 |
| Previous Close | 0.159 |
| Day's Range | 0.157 - 0.163 |
| 52-Week Range | 0.140 - 0.890 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2024 |
About SCPX
Scorpius Holdings Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company provides analytical testing, downstream process development, formulation optimization and development, and clinical biomanufacturing services to pharmaceutical and biotech companies. It is also involved in the provision of pre-clinical and product development; chemistry, manufacturing, and control analytical support; and bioassays. The company was formerly known as NightHawk Bioscie... [Read more]
Financial Performance
In 2022, SCPX's revenue was $6.38 million, an increase of 202.12% compared to the previous year's $2.11 million. Losses were -$43.43 million, 23.8% more than in 2021.
Financial StatementsNews
Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University
DURHAM, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX), an integrated contract development and manufacturing organization (CDMO), today announced that it has bee...
Scorpius Holdings Accepted as a Member of the US Government's BioMaP-Consortium
Provides Access to Growth Funding and Enhanced Access to Federal Projects Provides Access to Growth Funding and Enhanced Access to Federal Projects
Scorpius Holdings, Inc. Announces Closing of Public Offering
DURHAM, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO),...
Scorpius Holdings, Inc. Announces Pricing of Public Offering
DURHAM, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO),...
Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock
DURHAM, N.C., March 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), ...
Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023
Estimates Sequential Reduction in the Fourth Quarter of 2023 Operating Loss by Over $3.3 Million or Approximately 30% Compared to the Third Quarter of 2023
NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today
DURHAM, N.C., Feb. 06, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences / Scorpius Holdings, Inc. (NYSE American: NHWK ; SCPX), an integrated contract development and manufacturing organization (CDMO),...
NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note
DURHAM, N.C., Jan. 30, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), to...
NightHawk's Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program
Project to benefit from Scorpius' comprehensive services in process development, bioanalysis, and cGMP manufacturing Project to benefit from Scorpius' comprehensive services in process development, bi...
NightHawk's Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client
Project reflects Scorpius' versatility through its multi-functional biologics facility and expertise in microbial fermentation Project reflects Scorpius' versatility through its multi-functional biolo...
NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO
Announces senior leadership appointments to further support client programs and growing sales pipeline Announces senior leadership appointments to further support client programs and growing sales pip...
NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University
Scorpius subsidiary to manufacture novel biologic targeting substance use disorder Scorpius subsidiary to manufacture novel biologic targeting substance use disorder
NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University
Next phase of multi-million-dollar project to include scaling up cGMP manufacturing for phase 1 trial targeting infectious disease
NightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical Company
Manufacturing run at Scorpius' state-of-the-art San Antonio microbial facility sets the stage for commercial manufacturing
NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets
Over $20 million in signed manufacturing contracts which include premier biotech/pharma companies and research institutes
NightHawk Biosciences Provides Q3 2023 Business Update
DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, a...
NightHawk Biosciences Provides Q2 2023 Business Update
DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and...
NightHawk Biosciences Provides Q1 2023 Business Update
DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and ...
NightHawk Biosciences Provides 2022 Year End Business Update
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate th...
NightHawk Biosciences Provides Third Quarter 2022 Business Update
DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the...
Nighthawk Biosciences' Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility
DURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the...
NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory
Further Enhances Research Capabilities in Infectious Disease and Biodefense Further Enhances Research Capabilities in Infectious Disease and Biodefense
Why NightHawk Biosciences Stock Is Soaring
NightHawk Biosciences Inc (AMEX:NHWK) shares are trading higher Monday after the company said it would fund development of a monkeypox vaccine.
NightHawk Biosciences Provides Second Quarter 2022 Business Update
DURHAM, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the...
Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today
DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing first-in-cla...